Product Description
Evobrutinib (M2951) is in clinical development to investigate its potential as a treatment for multiple sclerosis (MS). It is an oral, highly selective inhibitor of BrutonÕs tyrosine kinase (BTK) which is important in the development and functioning of various immune cells including B lymphocytes and macrophages.ÊEvobrutinib is designed to inhibit primary B cell responses such as proliferation and antibody and cytokine release, without directly affecting T cells. Evobrutinib is currently under clinical investigation and not approved for any use anywhere in the world. (Sourced from: https://www.emdgroup.com/en/news/evobrutinib-14-10-2021.html)
Mechanisms of Action: Btk Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck KGaA
Company Location: GERMANY HRB 6164 I8
Company CEO: Belen Garijo
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Germany, United Kingdom
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Multiple Sclerosis
Phase 2: Total Knee Arthroplasty
Phase 1: Breast Cancer|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Phase III Study of Evobrutinib in RMS (EVOLUTION RMS 1) | P3 |
Active, not recruiting |
Multiple Sclerosis |
2027-02-05 |
|
| Phase III Study of Evobrutinib in RMS (EVOLUTION RMS 2) | P3 |
Active, not recruiting |
Multiple Sclerosis |
2026-12-21 |
|
| 2016-001448-21 | P2 |
Active, not recruiting |
Multiple Sclerosis |
2025-04-25 |
|
| MS200527_0091 | P1 |
Completed |
Healthy Volunteers |
2023-02-14 |
28% |